Epstein-Barr virus latent membrane protein 1-derived peptide epitopes presented on MHC class II molecules (LMP1-MHC II complex)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is a primary oncogenic protein that functions as a constitutively active mimic of the CD40 receptor, activating pathways such as NF-kappaB, JNK, and PI3K to drive B-cell proliferation and survival (UniProt P03230). Peptide epitopes derived from the processing of LMP1 are presented on the cell surface by Major Histocompatibility Complex (MHC) class II molecules, where they serve as essential targets for recognition by CD4+ T cells (PubMed: 15140914). These peptide-MHC complexes are highly relevant in the context of EBV-associated malignancies, including nasopharyngeal carcinoma and various lymphomas, where LMP1 is frequently expressed during viral latency (PubMed: 24501210). Therapeutic strategies targeting these epitopes include adoptive T-cell therapies, such as EBV-specific cytotoxic T lymphocytes, and therapeutic vaccines designed to enhance the host immune response against latently infected cells. However, the effectiveness of targeting these complexes can be hindered by viral mechanisms of immune evasion, such as the downregulation of MHC class II expression or the creation of an immunosuppressive tumor microenvironment (PubMed: 19413161).

Other names

EBV LMP1 MHC class II epitopesLMP1-derived HLA class II-restricted peptidesLMP1 CD4+ T cell epitopesEpstein-Barr virus LMP1 antigen-MHC II complex

Recognition by T-cell receptors (TCRs) on CD4+ T cells, triggering immune-mediated lysis of EBV-infected cells and cytokine production to coordinate the anti-viral response.